APEX Pharma successfully renews EDA accreditation in accordance with Level 3 maturity standards — and secures accreditation from Uganda as well.

Reaching this level represents one of the most significant global benchmarks, awarded to regulatory bodies and companies that maintain highly advanced, robust, and quality-driven manufacturing and control systems.

Dr. Magdy Elba, Chairman of the Board, stated that the Egyptian Drug Authority’s achievement of the World Health Organization’s Maturity Level 3 represents a significant leap for Egypt’s pharmaceutical sector. It demonstrates the strength of the national regulatory system and its ability to efficiently oversee the manufacturing and distribution of medicines and vaccines. He noted that the Egyptian Drug Authority is the first in Africa to reach this advanced level, reinforcing Egypt’s regional standing and confirming the competitiveness of the Egyptian pharmaceutical industry in global markets.

He emphasized that this milestone reflects APEX Pharma’s commitment to advancing its manufacturing capabilities and strengthening quality systems across its facilities. He pointed out that the company operates under a rigorous framework that ensures the production of safe and effective medicines that meet the needs of the Egyptian market while fully complying with international standards applied in developed countries. He added that this accreditation crowns the company’s continuous efforts in upgrading production lines, monitoring systems, auditing processes, and internal quality controls.

Elba also highlighted that APEX Pharma’s manufacturing facility is certified by the Saudi Food and Drug Authority (SFDA), having successfully passed inspection requirements and complied with the advanced quality and manufacturing standards adopted in the Saudi Kingdom—an achievement that underscores the high level of excellence reached by pharmaceutical plants in Egypt.

Dr.Magdy Elba revealed that APEX Pharma recently secured official approval from Uganda to begin registering and exporting its products to the Ugandan market, supporting company’s external expansion plans.

In the same context, the company announced the opening of its new manufacturing state of art plant in the Kingdom of Saudi Arabia—the first overseas production expansion for an Egyptian pharmaceutical company. This move aims to strengthen APEX Pharma’s capacity to meet the needs of the Gulf markets and localize high-quality pharmaceutical manufacturing within the Kingdom. The opening of this facility comes as part of APEX Pharma’s strategy to evolve into a prominent regional player in the pharmaceutical industry by reinforcing its direct presence in Arab markets and delivering products fully aligned with Saudi and international standards.